AT290528B - Verfahren zur Herstellung von neuen 5-NR<1>R<2>-6-Chlor-1H-imidazo[4,5-b]pyrazin-2-onen und ihren Salzen - Google Patents

Verfahren zur Herstellung von neuen 5-NR<1>R<2>-6-Chlor-1H-imidazo[4,5-b]pyrazin-2-onen und ihren Salzen

Info

Publication number
AT290528B
AT290528B AT1082569A AT1082569A AT290528B AT 290528 B AT290528 B AT 290528B AT 1082569 A AT1082569 A AT 1082569A AT 1082569 A AT1082569 A AT 1082569A AT 290528 B AT290528 B AT 290528B
Authority
AT
Austria
Prior art keywords
pyrazin
imidazo
chloro
ones
salts
Prior art date
Application number
AT1082569A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of AT290528B publication Critical patent/AT290528B/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT1082569A 1968-11-20 1969-11-19 Verfahren zur Herstellung von neuen 5-NR<1>R<2>-6-Chlor-1H-imidazo[4,5-b]pyrazin-2-onen und ihren Salzen AT290528B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77747868A 1968-11-20 1968-11-20

Publications (1)

Publication Number Publication Date
AT290528B true AT290528B (de) 1971-06-11

Family

ID=25110370

Family Applications (1)

Application Number Title Priority Date Filing Date
AT1082569A AT290528B (de) 1968-11-20 1969-11-19 Verfahren zur Herstellung von neuen 5-NR<1>R<2>-6-Chlor-1H-imidazo[4,5-b]pyrazin-2-onen und ihren Salzen

Country Status (10)

Country Link
US (1) US3567725A (de)
AT (1) AT290528B (de)
BE (1) BE741910A (de)
BR (1) BR6914329D0 (de)
DE (2) DE1957711A1 (de)
FR (1) FR2035817B1 (de)
GB (1) GB1246006A (de)
IL (1) IL33336A0 (de)
NL (1) NL6915957A (de)
ZA (1) ZA698081B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8810934D0 (en) * 1987-05-26 1988-06-15 Ici America Inc Amides
GB8810933D0 (en) * 1987-05-26 1988-06-15 Ici America Inc Heterocyclic compounds
US5705585A (en) * 1993-06-30 1998-01-06 Arqule, Inc. Aminimide-containing molecules and materials as molecular recognition agents
JPH09507852A (ja) * 1994-01-05 1997-08-12 アーキュール,インコーポレーテッド 特定の性質を有するポリマーの製造方法
US7034110B2 (en) * 1994-01-05 2006-04-25 Arqule, Inc. Method of identifying chemical compounds having selected properties for a particular application
US5734082A (en) * 1994-10-20 1998-03-31 Arqule Inc. Hydroxyethyl aminimides
US5712171A (en) * 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
WO1996031263A1 (en) * 1995-04-06 1996-10-10 Arqule, Inc. Method for rapid purification, analysis and characterization of collections of chemical compounds
US5962412A (en) * 1996-06-10 1999-10-05 Arqule, Inc. Method of making polymers having specific properties
ES2627352T3 (es) * 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
BR112012009751A2 (pt) 2009-10-26 2020-09-24 Signal Pharmaceuticals, Llc métodos de síntese e purificação de heteroarila
TWI758746B (zh) 2011-10-19 2022-03-21 美商標誌製藥公司 以tor激酶抑制劑治療癌症
MY169749A (en) 2011-12-02 2019-05-15 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
ES2742398T3 (es) 2012-02-24 2020-02-14 Signal Pharm Llc Métodos para tratar el cáncer de pulmón no microcítico usando una terapia de combinación de inhibidores de TOR quinasa
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
TW201441227A (zh) 2013-01-16 2014-11-01 Signal Pharm Llc 經取代吡咯并嘧啶化合物、其組合物及其治療方法
EP2986298A1 (de) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Behandlung von krebs mit dihydropyrazino-pyrazinen
BR112015026247B1 (pt) 2013-04-17 2022-08-23 Signal Pharmaceuticals, Llc Uso de compostos em combinação com um análogo de citidina, composição farmacêutica que os compreende, e kit
SG11201508527VA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
CA2909625C (en) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
BR112015026257B1 (pt) 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
WO2014172425A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
US9358232B2 (en) 2013-04-17 2016-06-07 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
GB201309508D0 (en) 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
CN113831345A (zh) 2013-05-29 2021-12-24 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
EP3131552B1 (de) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Verfahren zur behandlung von krebs anhand einer tor-kinasehemmerkombinationstherapie
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
EA201790189A1 (ru) 2014-07-14 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
AU2018289539B2 (en) 2017-06-22 2024-07-04 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection

Also Published As

Publication number Publication date
FR2035817B1 (de) 1973-01-12
BE741910A (de) 1970-05-19
ZA698081B (en) 1971-07-28
GB1246006A (en) 1971-09-15
IL33336A0 (en) 1970-01-29
NL6915957A (de) 1970-05-22
DE1957711A1 (de) 1970-06-18
DE1965989A1 (de) 1971-02-18
BR6914329D0 (pt) 1973-02-22
FR2035817A1 (de) 1970-12-24
US3567725A (en) 1971-03-02

Similar Documents

Publication Publication Date Title
AT290528B (de) Verfahren zur Herstellung von neuen 5-NR&lt;1&gt;R&lt;2&gt;-6-Chlor-1H-imidazo[4,5-b]pyrazin-2-onen und ihren Salzen
AT294113B (de) Verfahren zur Herstellung von neuen 3,4-Dihydro-2H-1,2-benzothiazin-1,1-dioxyden und ihren Salzen
AT295511B (de) Verfahren zur Herstellung von neuen Phenoxyaminopropanolderivaten und ihren Salzen
AT304535B (de) Verfahren zur Herstellung von neuen 2-(Thienyl-3&#39;-amino)-1,3-diazacycloalkenen-(2) und ihren Salzen
AT321277B (de) Verfahren zur Herstellung von neuen 1,3-Diphenyl-propan-1-onen und ihren Salzen
AT288378B (de) Verfahren zur Herstellung von neuen 1,2,5-Thiadiazolderivaten und ihren Salzen
AT303053B (de) Verfahren zur Herstellung von neuen 1,1,1-Trichloräthan-Derivaten und ihren Salzen
AT291250B (de) Verfahren zur Herstellung von neuen 5-NR&lt;1&gt;R&lt;2&gt; -6-Chlor-1H-imidazo[4,5-b]pyrazin-2-onen
AT286290B (de) Verfahren zur Herstellung von neuen Pyridoindolderivaten und ihren Salzen
AT269166B (de) Verfahren zur Herstellung von neuen p,p&#39;-Dialkanoyldiphenylharnstoff-bis-guanylhydrazonen und ihren Salzen
AT299193B (de) Verfahren zur Herstellung von neuen Imidazolidinochinalinderivaten und ihren Salzen
AT289789B (de) Verfahren zur Herstellung von neuen 1,2,5-Thiadiazolderivaten und ihren Salzen
AT315862B (de) Verfahren zur Herstellung von neuen Diazepinderivaten und ihren Additionssalzen
AT286289B (de) Verfahren zur Herstellung von neuen Pyridoindolderivaten und ihren Salzen
AT287694B (de) Verfahren zur Herstellung von neuen Imidazolindinderivaten und ihren Salzen
AT295756B (de) Verfahren zur Herstellung von neuen Steroid-17&amp;alpa;,21-orthocarbonaten
AT288416B (de) Verfahren zur Herstellung von neuen Benzoxazinderivaten und ihren Salzen
AT307399B (de) Verfahren zur Herstellung von neuen basischen Dithienylpropen-Derivaten und ihren Salzen
AT315844B (de) Verfahren zur Herstellung von neuen basisch substituierten 2,3,7,8-Tetrahydro-1H-chino[1,8-ab][1]benzazepinen und von ihren Salzen
AT286299B (de) Verfahren zur herstellung von neuen 1-substituierten 6,7-dimethoxy-isochinolinen und ihren salzen
AT304488B (de) Verfahren zur Herstellung von neuen 9-Aminoalkyl-9,10-dihydro-9,10-äthano-anthrazenen und ihren Salzen
AT294112B (de) Verfahren zur Herstellung von neuen 3-Aryl-benzazinen und ihren Salzen
AT303749B (de) Verfahren zur Herstellung von neuen 3,4-Dihydro-oxathiazin-4-on-2,2-dioxyden und ihren Salzen
AT299196B (de) Verfahren zur Herstellung von neuen 5-Aryl-3H-1,2,4-dithiazolen und ihren Salzen
AT285620B (de) Verfahren zur Herstellung von neuen 1,2-Oxazinderivaten und ihren Salzen

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee